San Francisco, 27 December 2018: The Report PharmacogenomicsTechnology/Theranostics/Companion Diagnostics (CDx) Market Analysis By
Therapeutic Area (Oncology Neurological, Cardiovascular, Immunology Disorders),
By Technology, And Segment Forecasts, 2018 - 2025
The global pharmacogenomics technology (theranostics and
companion diagnostics) market is expected
to reach USD 18.3 billion by 2025, according to a new report by Grand View
Research, Inc. Diagnostics is coming to grips with the wave of pharmacogenomic
tests that are followed by new biological therapy introductions. These tests
enable cost-effective treatment and also add value to the process of
drug-development. Advantages associated with the usage of these tests such as
disease risk prediction, patient stratification, and therapeutic response
monitoring over the traditional methods is anticipated to significant source of
progress in this market.
In addition, pharmacogenomics testing
products aid physicians in individualizing and optimization of patient’s
therapeutic regimen. Pharmacogenomics and theranostics are paving the way for
integrated medicine. Rapid evolution in this group of specialized molecular
diagnostic tests are contributing in improvement for assessment of real-time
treatment of disease.
However, presence of challenges pertaining
to early integration of pharmacogenomic based testing into drug development
time lines for gaining the approval simultaneously is anticipated to impede
growth. Proper designing and implementation of clinical trials in order to
identify individual as well as population variations from a given therapy has
become a necessary attribute for the success of theranostics.
Access Research Report of Companion Diagnostics Market @ www.grandviewresearch.com/industry-analysis/pharmacogenomics-technology-theranostics-companion-diagnostics-cdx-market
Further key findings from the report suggest:
· Oncology is estimated to account for the
largest revenue share owing to the presence of substantial number of products
in this segment
· Furthermore, precision oncology
investigators envision in giving multiple medications, in varied sorts of
combinations, in an effort to squelch a tumor rather than just temper its
growth
· Aforementioned fact is responsible for the
estimated revenue share of cancer in pharmacogenomics technology market
· Polymerase Chain Reaction (PCR) was the
largest revenue grossing segment of the with respect to technology for
theranostics
· Advantages associated with the use of the
PCR technique makes it current workhorse of clinical diagnostics
· Moreover, reproducible and precise results
produced with the assays without sacrificing the sensitivity are responsible
for the estimated share
· North American region dominates the market
as a consequence of economic incentives for drug developers to pair their
products with diagnostics.
· Asia Pacific market is projected to
showcase fastest growth over the forecast period as the companies are engaged
in capturing untapped opportunities
· Key players operating include F Hoffman La
Roche, Agilent Technologies, Thermo Fisher Scientific Inc., GE Healthcare,
Pfizer, Qiagen NV, Leica Biosystems Nussloch GmBH, and Foundation Medicine.
· Diagnostic companies are positioning
themselves to offer theranostic tools by widening the application of in-vitrodiagnostic
technologies to include more than just disease detection
Browse more reports of
this category by Grand View Research at: www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has segmented the
pharmacogenomics technology (theranostics and companion diagnostics) market on
the basis of therapeutic area, technology, and region:
Therapeutic Area Outlook (Revenue, USD Million; 2014 - 2025)
·
Oncology
·
Neurological Disorders
·
Cardiovascular Disease
·
Immunological Disorders
·
Others
Technology Outlook (Revenue, USD Million;
2014 - 2025)
·
PCR
·
In-situ Hybridization
·
Immunohistochemistry
·
Sequencing
·
Others
Regional Outlook (Revenue, USD Million;
2014 - 2025)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East & Africa
Access Press Release of
Companion Diagnostics Market@ www.grandviewresearch.com/press-release/global-pharmacogenomics-technology-theranostics-companion-diagnostics-cdx-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment